Metformin in the therapy of diabetes;METFORMIN IN DER DIABETESTHERAPIE

Internist

Volumn 39, Issue 2, 1998, Pages 222-228

  Mehnert, H ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ABDOMINAL PAIN; ANOREXIA; DIABETES MELLITUS; DIARRHEA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; LACTIC ACIDOSIS; LIPID METABOLISM; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; TASTE DISORDER;

BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERINSULINISM; METFORMIN; OBESITY;

EID: 0031937544     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050161     Document Type: Review

References (36)

1. Bailey CJ (1992) Biguanides and NIDDM. Diabetes Care 15:755-772
2. Berchtold B, Bolli P, Arbenz U, Keiser L (1969) Intestinale Absorptionsstörung infolge Metforminbehandlung (Zur Frage der Wirkungsweise der Biguanide). Diabetologia 5:405
3. Bloomgarden ZT (1996) Conference report: Renal disease, metformin, and the adipocyte. Diabetes Care 19:1038
4. Carlsen SM, Rossvoll O, Bjerve KS, Foiling J (1996) Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Int Med 239:227
5. Chaudhuri A, Rashmi T, Mohanty P, Szudzik E, Bandyopadhyay A, Arien M, Thusu K, Dandona P (1997) The combination of insulin and metformin in treatment of non-insulin dependent diabetes mellitus (NIDDM). Diabetes 46 [Suppl 1] 334 A:1276
6. Cusi K, Consoli A, De Fronzo R (1996) Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4059
7. De Fronzo RA, Barzilai N, Simonson, DC (1991) Mechanism of metformin action in obese and lean non-insulindependent diabetic subjects. J Clin Endocrinol 73:1294-1301
8. Dornan TL, Heller SR, Peck GM, Tattersall RB (1991) Doubleblind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 14:3422-3444
9. Fanghänel G, Sánchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J (1996) Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 19:1185-1189
10. Galuska D, Zierath J, Thörne A, Sonnenfeld T, Wallberg-Henriksson H (1991) Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle. Diabète et Metab 17:159-163
11. Grant PJ (1996) The effects of high-and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 19:64-66
12. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H (1989) Orale antidiabetische Kombinationstherapie mit Sulfonylharnstoffen und Metformin. Med Welt 40:118
13. Haupt E, Panten U (1997) Die Stellung der Biguanide in der Therapie des Diabetes mellitus. Med Klin 92:472
14. Hermann LS, Melander A (1992) Biguanides: Basic aspects and clinical uses. In: Alberti KGMM, De Fronzo RA, Keen H, Zimmet P (Hrsg) International Textbook of Diabetes Mellitus, Wiley, Chichester, pp 773-796
15. Jurovich MR, Wooldridge JD, Force RW (1997) Metformin-associated non ketotic metabolic acidosis. Ann Pharmacotherapy 31:53
16. Lalau JD, Lacroix C, Compagnon P, De Cagny B, Rigaud JP, Bleichner G, Chauveau P, Dulbecco P, Guérin C, Haegy JM, Loirat P, Marchand B, Ravaud Y, Weyne P, Fournier A (1995) Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 18:779-787
17. Marquie G (1983) Metformin action on lipid metabolism in lesions of experimental aortic atherosclerosis of rabbits. Atherosclerosis 47:7-17
18. McLelland J (1985) Recovery from metformin overdose. Diabet Med 2:410-411
19. Mehnert H, Seitz W (1958) Weitere Ergebnisse der Diabetesbehandlung mit blutzuckersenkenden Biguaniden. Münch Med Wochenschr 100:1849
20. Nagi DK, Ali VM, Yudkin JS (1996) Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with noninsulin-dependent (type 2) diabetes mellitus. Diab Med 13:753
21. Nosadini R, Avogaro A, Trevisan R, Valerio A, Tessari P, Tiengo A, Crepaldi G (1987) Effecton metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type 2 diabetes. Diabetes Care 10:62-67
22. Pastore L, Morviducci L, Merante O, Giaccari A, Tamburrano L (1997) Combined glibenclamide plus metformin improves insulin sensitivity in non obese NIDDM patients. Diabetes 46 [Suppl 1] 101 A:400
23. Periello G, Di Matteo G, Pampanelli S, Santamaria G, Picchio E, Santersanio F (1997) Metformin associated to insulin therapy for treatment of obese NIDDM. Diabetes 46 [Suppl 1] 154 A:593
24. Prager R, Schernthaner G (1983) Insulin receptor binding to monocytes, insulin secretion and glucose tolerance following metformin treatment. Diabetes 32:1083-1086
25. Ross S, Hunt J, Josse R (1992) Acarbose significantly improves glucose-control in NIDDM-subjects, results of the Multicenter Canadian Trial. Diabetes 41:193 A
26. Safadi R, Dranitzki-Elhalel M, Poportzer M, Ben-Yehuda A (1996) Metformin-induced lactic acidosis associated with acute renal failure. Am J Nephrol 16:520
27. Sambol NC, Chiang J, O'Conner M, Liu ChY, Liu ET, Goodman AM, Benet LZ, Karam JH (1996) Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulindependent diabetes mellitus. J Clin Pharmacol 36:1012
28. Schäfer G (1983) Biguanides: a review of history, pharmacodynamics and therapy. Diabet Metab Rev 9:148-163
29. Schernthaner G (1992) Kritische Analyse der antidiabetischen Therapie mit Metformin: Stoffwechselwirkungen, antiatherogene Effekte und Kontraindikationen. Akt Endokrinol 13:44-50
30. Standl E, Janka HU, Mehnert H (1994) Behandlung mit nicht-insulinotropen oralen Antidiabetika. In:Mehnert H, Schoffling K, Standl E, Usadel KH (Hrsg) Diabetologie in Klinik und Praxis, 3. Aufl. Thieme, Stuttgart, S 211-229
31. Sulkin ThV, Bosman D, Krentz AJ (1997) Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 20:925
32. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235-246
33. Velasquez EM, Mendoza SG, Wang P, Glueck ChJ (1997) Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor 1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovaric syndrome. Metabolism 48:454
34. Widen IEM, Erikson JG, Groop LC (1992) Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 41:354-358
35. Wollen N, Bailey CJ (1988) Inhibition of hepatic gluconeogenesis by metformin: synergism with insulin. Biochem Pharmacol 37:4353-4358
36. Wu MS, Johnston P, Sheu WWHH, Hollenbeck CB, Jeng CY, Goldfine ID, Chen YDI, Reaven GM (1990) Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13:1-8